OSAKA, Japan & CAMBRIDGE, Mass. & HONG KONG & SHANGHAI & FLORHAM PARK, N.J.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (HUTCHMED) today ...

OSAKA, Japan & CAMBRIDGE, Mass. & HONG KONG & SHANGHAI & FLORHAM PARK, N.J.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and HUTCHMED (China) Limited (Nasdaq/AIM:HCM ...

Adding a targeted agent to second-line chemotherapy significantly improved progression-free survival (PFS) but not overall survival (OS) in advanced gastric cancer, a large randomized trial showed.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and ...

In a late-stage study presented at the American Society of Clinical Oncology meeting, Hutchison China MediTech’s VEGF inhibitor fruquintinib showed it could help relapsed patients with advanced ...

Hong Kong, Shanghai & Florham Park, NJ — Wednesday, February 7, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that data from FRUTIGA, HUTCHMED’s Phase III ...

image: Josep Tabernero, Director of the Vall d’Hebron Institute of Oncology (VHIO), Head of the Medical Oncology Department at the Vall d’Hebron University Hospital (HUVH). view more Published in The ...

HUTCHMED and Innovent Biologics announced that their FRUSICA-2 Phase II/III clinical trial of fruquintinib combined with sintilimab for the treatment of advanced renal cell carcinoma (RCC) in China ...

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and ...